Monday, April 26, 2021

Antibiotic Strategies for Success - A Bridge to Nowhere?

›
  This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech. Among other things, we pursued a discus...
2 comments:
Monday, April 5, 2021

Pull American - Why Not?

›
  In a sleepy moment I had an inspiration. Funding a pull incentive for antibiotic R&D in the US (like a market entry reward for example...
1 comment:
Friday, March 12, 2021

The Pew Trust Analysis of the Antibacterial Pipeline

›
  The Pew Charitable Trust just posted their analysis of the antibacterial pipeline.     They provide two separate analyses, one for   antib...
Monday, February 15, 2021

Pull Incentives and AMR - Is Europe up to the Task?

›
  I have been saying for years that for a pull incentive to actually function as an incentive, it must be large enough to motivate investors...
Monday, February 8, 2021

Covid vaccines compared to AMR

›
  I never dreamed this would be possible. Of course, so many things are possible today that I thought were impossible that I’m almost embarr...
Friday, February 5, 2021

AMR - a Holistic Approach

›
  A very important   report   on the state of antibiotic use and resistance globally has just been release by The Center for Disease Dynamic...
Monday, October 26, 2020

The Pasteur Act - A View from Industry

›
Chris Burns   Evan Loh We will continue our discussion of the Pasteur Act as proposed by Senators Bennet and Young. Today I discuss the bill...